| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Diabetes Type 1 Autoantibody Panel
Test Code13621
CPT Codes
86337, 86341 (x3)
Includes
Glutamic Acid Decarboxylase 65 Ab
Insulin Autoantibody
IA-2 Antibody
Zinc Transporter 8 (ZnT8) Antibody
Insulin Autoantibody
IA-2 Antibody
Zinc Transporter 8 (ZnT8) Antibody
Preferred Specimen
4 mL serum
Minimum Volume
2 mL
Transport Container
Transport tube
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 7 days
Frozen: 28 days
Refrigerated: 7 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Lipemia • Icterus • Specimens other than serum
Methodology
Enzyme Linked Immunosorbent Immunoassay (ELISA) • Radiobinding Assay (RBA)
Setup Schedule
Set up: Wed, Sat; Report available: 5-6 days
Clinical Significance
The American Diabetes Association supports using autoantibody (AAb) screening to diagnose T1D. T1D autoantibodies are markers of ongoing damage to insulin-producing beta cells. The four AAbs used in clinical practice to diagnose T1D are: AAbs against insulin (IAA), tyrosine phosphatase IA2 (IA2A), glutamic acid decarboxylase (GAD65), and zinc transporter. Numerous clinical trials demonstrate important clinical benefits associated with detecting T1D using an AAb screening approach.
Clinical guidelines have been established to help identify T1D at its earliest phases and before progression to DKA, providing presymptomatic and symptomatic staging of T1D.
Clinical guidelines have been established to help identify T1D at its earliest phases and before progression to DKA, providing presymptomatic and symptomatic staging of T1D.
